首页AutophagyCXCR
CXCR
T10635 Burixafor hydrobromide Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in treating choroid neova
T10905 CXCR2-IN-1 CXCR2-IN-1 has a pIC50 of 9.3 and is a CXCR2 antagonist of the central nervous system penetration agent.
T11140 E6130 E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration.
T11179 Elubrixin  Elubrixin inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin can be used for inflammatory diseases such as inflammatory bowe
T12269 NUCC-390 NUCC-390 is a selective agonist of small-molecule CXCR4 receptor.
T12269L NUCC-390 dihydrochloride NUCC-390 dihydrochloride is selective agonist of small-molecule CXCR4 receptor.
T12705 Reparixin L-lysine salt Reparixin L-lysine salt is an allosteric chemokine receptor 1/2 (CXCR1/2) activation inhibitor.
T14665 Motixafortide Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM).
T16850 SB-265610 SB-265610 is a nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil c
T16864 SCH 563705 SCH 563705 is an effective and orally available CXCR2 and CXCR1 antagonist (IC50s: 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively).
T16933 SRT3190 SRT3190 is an antagonist of CXCR2.
T17208 USL311 USL311 is a selective antagonist of CXCR4. USL311 prevents the binding of stromal-cell derived factor-1 to CXCR4.
T1739 WZ811 WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).
T1776 Plerixafor Plerixafor, a chemokine receptor antagonist, blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4.
T1776L AMD 3100 octahydrochloride AMD 3100 octahydrochloride blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bo
T19385 ITIC-4F ITIC-4F has broad applicability in high-efficiency binary and ternary single-junction as well as tandem polymer solar cells (PSCs).ITIC-4F is an indacenodithienothiophene (IDTT)-ba
T19386 ITIC ITIC has a superior thermal stability and undergoes a glass-crystal transition considerably below its high Tg of 180 °C. ITIC, non-fullerene acceptor, is an indacenodithienothioph
T1955 SB225002 SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2.
T2477 UNBS-5162 UNBS-5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
T3047 SRT3109 SRT3109 is a CXCR2 ligand used in the treatment of chemokine mediated diseases and conditions.
T3327 Arteether Arteether is a new, fast-acting antimalarial drug.
T3396 Baohuoside I Baohuoside I is a component of Epimedium koreanum, exhibits anti-inflammatory activity and anti-osteoporosis activities.
T3992 MSX-122 MSX-122 is a novel small molecule and partial CXCR4 antagonist, with potent inhibition of CXCR4/CXCL12 actions(IC50 = 10 nM).
T4032 MSX-127 MSX-127 elicites positive response in peptide CXCR4.
T4033 MSX-130 MSX-130 is CXCR4 Antagonist.
T4163 Repertaxin Reparixin is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxi
T5193 Danirixin Danirixin is a potent antagonist of CXCR2 that inhibits IL-8 binding to CXCR2 (IC50: 12.5 nM).
T5207 LIT-927 LIT-927 is an orally active CXCL12 neutraligand (Ki: 267 nM for CXCL12 binding to CXCR4).
T5849 JMS-17-2 JMS-17-2 is a potent and selective antagonist of CX3CR1( IC50 : 0.32 nM).
T6764 ATI-2341 ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of
T7130 Navarixin Navarixin(SCH527123) is a novel, selective CXC chemokine receptor 2(CXCR2) antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, cha
T7681 AZD-5069 AZD-5069 is an chemokine receptor 2 antagonist (CXCR2; IC50 = 0.79 nM).
T8497 SX-682 SX-682 is a potent, selective and orally bioavailable inhibitor of CXCR1/2 ,has the potential to treat castration-resistant prostate cancer.
TN5227 (+/-)-Vestitol Vestitol has antioxidation, anti-inflammatory and antimicrobial activities, it can strongly act in a low dose and concentration and have a promising potential to be applied in the
TP2141 Balixafortide TFA Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC50 < 10 nM). It shows 1000-fold selective for CXCR4 than a large panel of receptors incl
TP2141L Balixafortide Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM and it is also a potent hematopoietic stem and progenitor cell (HSPC)
TQ0174 AMD-070 Mavorixafor (AMD-070) is a selective and orally available CXCR4 antagonist (IC50: 13 nM against CXCR4 125I-SDF binding) and also inhibits the replication of T-tropic HIV-1 (NL4.3 s
  • 关注公众号
    - 超值特惠
    - 客户福利
    - 业界动态
    - 实用攻略
陶素的所有产品和服务仅用于科学研究,我们不为任何其他用途提供产品和服务(也不为任何个人提供产品和服务)。